Jamjoom Pharma and Mubadala Bio’s Bioventure Healthcare forge partnership to expand patient access to specialty pharmaceutical care
A landmark collaboration between two leading healthcare organisations brings enhanced commercial reach and expertise to serve patients throughout the United Arab Emirates.
Jamjoom Pharma and Bioventure Healthcare, a subsidiary of Mubadala Bio, have announced a strategic partnership designed to expand patient access to Ustekinumab across the United Arab Emirates. The agreement positions Jamjoom Pharma as the exclusive commercial partner for the specialised pharmaceutical product, combining the distinctive capabilities of both organisations to serve the nation’s healthcare community with enhanced efficiency and care.
The partnership draws together complementary strengths that have been refined through years of dedicated service within the healthcare sector. Jamjoom Pharma brings its established commercial presence, considerable scale and profound experience in engaging healthcare professionals across the United Arab Emirates and the broader Middle East and Africa region. Bioventure Healthcare contributes its distinguished pharmaceutical portfolio and quality capabilities, enabling a seamless integration of innovation with proven commercial acumen.
Under the terms of the agreement, Jamjoom Pharma will lead the compliant commercialisation of the product, ensuring that all activities meet applicable regulatory requirements whilst fostering meaningful engagement with healthcare professionals throughout the nation. This structured approach reflects an unwavering commitment to maintaining the highest standards of excellence and integrity within the pharmaceutical sector.
The collaboration exemplifies both organisations’ dedication to strengthening patient access to specialty care, a cornerstone of the UAE’s evolving healthcare landscape. By uniting their respective expertise and resources, the partners are positioned to enhance the delivery of advanced pharmaceutical treatments to those who benefit from such specialised interventions.
This partnership represents a meaningful contribution to supporting the UAE’s healthcare ecosystem, reinforcing the nation’s position as a centre of pharmaceutical excellence and innovation. The agreement underscores the importance of collaborative approaches in advancing healthcare outcomes and ensuring that patients throughout the Emirates have access to the treatments and expertise they require.
On Simply Luxury: Mubadala